Euroopa Liit - eesti - EMA (European Medicines Agency)

celgene europe bv - asatsitidiin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastilised ained - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 25mg 110tk; 25mg 28tk; 25mg 56tk; 25mg 30tk; 25mg 100tk; 25mg 90tk; 25mg 70tk; 25mg 98tk; 25mg 84tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 50mg 30tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 12,5mg 30tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 37,5mg 84tk; 37,5mg 30tk; 37,5mg 56tk; 37,5mg 28tk

Eesti - eesti - Ravimiamet

teva b.v. - sunitiniib - kõvakapsel - 50mg 28tk; 50mg 30tk

Eesti - eesti - Ravimiamet

teva b.v. - sunitiniib - kõvakapsel - 12,5mg 30tk

Eesti - eesti - Ravimiamet

teva b.v. - sunitiniib - kõvakapsel - 25mg 28tk

Eesti - eesti - Ravimiamet

mylan ireland limited - sunitiniib - kõvakapsel - 12,5mg 30tk

Eesti - eesti - Ravimiamet

mylan ireland limited - sunitiniib - kõvakapsel - 50mg 28tk